Pfizer stops one of two Phase 3 trials for sickle cell drug, still plans to seek approval in 2026
Pfizer terminated one of two late-stage trials for a sickle cell treatment candidate from its $5.4 billion acquisition of Global Blood …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
